Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Hoffmann-La Roche
University of Washington
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
Spanish Oncology Genito-Urinary Group
Hoosier Cancer Research Network
National Cancer Institute (NCI)
Hoffmann-La Roche
UNICANCER
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Eli Lilly and Company
Radiation Therapy Oncology Group
SWOG Cancer Research Network
Hoosier Cancer Research Network
Altor BioScience
University of Rochester
Ankara Etlik City Hospital
Queen Mary University of London
Shanghai Zhongshan Hospital
National Cancer Institute (NCI)
Emory University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Nektar Therapeutics
Mayo Clinic
Hoosier Cancer Research Network
Radiation Therapy Oncology Group
Sun Yat-sen University
Masonic Cancer Center, University of Minnesota
University Health Network, Toronto
Chinese PLA General Hospital
Children's Oncology Group
UNICANCER
UNICANCER
Radiation Therapy Oncology Group
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Peking University Cancer Hospital & Institute
Cardiff University
Wake Forest University Health Sciences
Radiation Therapy Oncology Group
Cardiff University
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center